Combination

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Immunoglobulin G, Merck, Cancer, Pembrolizumab, Lung cancer, AACR, DLT, Clinical trial, Merck & Co., Kineta, NK, VISTA, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • Patients currently enrolled in the trial will be permitted to continue to participate.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Combination, Irinotecan, Patient, Gene, FOLFIRINOX, Oncolytic adenovirus, Cancer, PDAC, Society, Therapy, Cell, Pharmaceutical industry

Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.

Key Points: 
  • Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
  • “We look forward to presenting data at the upcoming ASGCT meeting that further highlight the potential of our systemically administered oncolytic adenovirus, VCN-01, to synergistically combine with an expanding range of standard-of-care chemotherapies for difficult-to-treat cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • “ Our on-going VIRAGE Phase 2b trial is evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC).
  • ET

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023

Retrieved on: 
Monday, April 1, 2024
Combination, Tax, COVID, Growth, Business, Form, Travel, Class, Sub, Business analyst, Adjustment, Investment, Depreciation, File, Mergers and acquisitions, Cryptocurrency

PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023.

Key Points: 
  • PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023.
  • I, a Delaware corporation (“Achari”) (NASDAQ: AVHI), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”).
  • Gross profit for the fourth quarter of 2023 decreased by 4.0% to $14.1 million, compared with a gross profit of $14.6 million for the same quarter of 2022.
  • Selling, general and administrative (SG&A) and R&D expenses for the fourth quarter of 2023 increased by 14.7% to $12.9 million, compared to $11.3 million for the fourth quarter of 2022.

Renesas Introduces New Entry-Level RA0 MCU Series with Best-in-Class Power Consumption

Retrieved on: 
Tuesday, April 9, 2024
Software, Hardware, Data Management, Consumer Electronics, IOT (Internet of Things), Technology, Other Manufacturing, Construction & Property, Artificial Intelligence, Semiconductor, Security, Building Systems, Manufacturing, Combination, Arm, Automation, Temperature, M23, Environment, Internet of things, Business, LQFP, Embedded, Library, Internet, BOM, MCU, Renesas Electronics, TRNG, Family, QFN, HOCO, Ecosystem, BSP, Series, Multimedia, HMI, FSP, AES, Building, Mobile phone

Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced the RA0 microcontroller (MCU) Series based on the Arm® Cortex®-M23 processor.

Key Points: 
  • Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced the RA0 microcontroller (MCU) Series based on the Arm® Cortex®-M23 processor.
  • The new, low-cost RA0 devices offer the industry’s lowest overall power consumption for general purpose 32-bit MCUs.
  • In addition, Renesas offers a Software Standby mode in the new MCUs that reduces power consumption by a further 99 percent to a miniscule 0.2 µA.
  • Renesas is now shipping the first group in the RA0 Series, the RA0E1 Group.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

The Kingdom of Saudi Arabia and Rezolve AI Ink Pioneering MOU to Establish Global AI Market Leaders

Retrieved on: 
Monday, March 18, 2024
AACI, Combination, Growth, Register, Partnership, Artificial intelligence, Acquisition, Business analyst, Ministry of Investment, KSA, Hallucination, MISA

LONDON, March 18, 2024 (GLOBE NEWSWIRE) -- In a strategic move that highlights the Kingdom of Saudi Arabia's commitment to technological advancement and economic growth, the Ministry of Investment of Saudi Arabia (MISA) has forged a groundbreaking partnership with Rezolve AI Limited. This collaboration is set to revolutionize the artificial intelligence (AI) landscape, establishing an AI Centre of Excellence in Saudi Arabia as a cornerstone of Vision 2030's innovation and development goals.

Key Points: 
  • Upon closing of the transaction, the combined company’s shares are expected to trade on the Nasdaq under the ticker symbol “ZONE”.)
  • This collaboration is set to revolutionize the artificial intelligence (AI) landscape, establishing an AI Centre of Excellence in Saudi Arabia as a cornerstone of Vision 2030's innovation and development goals.
  • • Creation of Global Market Leaders: In partnership with the Ministry of Investment, the goal is to launch at least five AI ventures in diverse market sectors, funded and headquartered locally, each aspiring to become global market leaders.
  • These ventures will leverage Rezolve's cutting-edge AI Large Language Model (brainpowa) to foster innovation and ensure global leadership without succumbing to AI hallucinations.

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Retrieved on: 
Monday, March 18, 2024
Combination, Fibromyalgia, Patent, Chronic pain, SILO, Ketamine, Therapy, Administration, Medical device

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO).

Key Points: 
  • The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
  • Silo believes that implantable drug delivery may be well-suited for chronic pain management.
  • “Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo.
  • If approved, SP-26 could be the first at-home approved ketamine based therapeutic.”
    The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.

Global Artificial Intelligence Market Expected to Grow to $1.3 Trillion by 2023

Retrieved on: 
Monday, March 18, 2024
Cloud, MSFT, Combination, Google Cloud, Algorithm, Natural language processing, Microsoft, Health, Ink, Social media, Artificial intelligence, Transport, Business analyst, Alphabet Inc., AV1, USD, Marketing, Cloud database, Armada, Automation, Amazon, Partnership, Internet of things, Oracle Cloud, VMW, PALM, BMR, Ministry of Investment, Hallucination, HP, VMware, Register, Microsoft Azure, Organization, Intelligence, Library, Internet, Research, News, Acquisition, PostgreSQL, KSA, Alliance for Open Media, Robotics, ACM, GOOG, ChatGPT, Machine learning, MISA, AACI, Nvidia, Growth, HP Inc., CUDA, NVDA, OCI, Table, A.I, Big, NVIDIA, Medical device

A report from MarketsAndMarkets said that the global artificial intelligence market size was valued at USD 150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030.

Key Points: 
  • A report from MarketsAndMarkets said that the global artificial intelligence market size was valued at USD 150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030.
  • The report added: “The increasing adoption of autonomous artificial intelligence (AI) is driving the growth of the Artificial Intelligence Industry.
  • As technology advances and more industries recognize its benefits, the Artificial Intelligence (AI) Market size is poised for expansion, fostering innovation and new opportunities.”   Active A.I.
  • MarketsAndMarkets continued: “The exponential ai growth statistics of digital data from various sources presents immense opportunities for the AI market.

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to April 13, 2024

Retrieved on: 
Friday, March 15, 2024
Combination, BRAC, Acquisition

Dallas, Texas, March 15, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on March 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to April 13, 2024 (the “Monthly Extension”).

Key Points: 
  • Dallas, Texas, March 15, 2024 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on March 11, 2024 it caused to be deposited $60,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.035 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to April 13, 2024 (the “Monthly Extension”).
  • The Monthly Extension is the third of the twelve monthly extensions permitted under the Company’s Amended and Restated Certificate of Incorporation, as amended to date.
  • On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement, as amended (the “Business Combination Agreement”), with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.